SMS Pharmaceuticals Ltd — Interim / Quarterly Report 2020

Feb 13, 2020

Registered & Corporate Office : Plot No. 72, H. No. 8·2·334/3 & 4, Road No. 5, Opp. SBI Executive Enclave, Banjara Hills, Hyder2bad • 500 034, Telangana, INDIA. Tel: +91·40·25259999, Fax : +91·40·2525 9889 CIN : L24239TG1987PLC008066 Email: info@smspharma.com, www.smspharma.com

Date: 13th February, 2020

To, The Manager, Corporate Filings Department, BSE Limited , Phiroze J eejeebhoy Towers, Dalal Street, Mumbai- 400 001

The Manager, Listing Compliance Department, National Stock Exchange of India Ltd, Exchange Plaza, Plot no. C /1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Sub: Limited Review Report with the UDIN

Further to our intimation on 12th February 2020, regarding the outcome of the unaudited financial results for the third quarter and nine months ended as on 31st December, 2019 we are enclosing the Limited Review Report along with the UDIN of the Statutory Auditor.

This is for your information and records.

Yours faithfully, For SMS Pharmaceuticals Limited

~ Secretary

Company

SURYANARAYANA & SURESH Chartered Accountants

Flat # C2, Millenium House, # 8-2-601/B, Road No. 10, Near Zaheer Nagar Cross Road, Banjara Hills, Hyderabad - 500 034. W : 040-233867~3 / 23386784 ~ : suryanarayanasuresh@gmail.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEDI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

Review Report to The Board of Directors SMS Pharmaceutica ls Limited

We have reviewed the accompanying statement of unaudited standalone financial results of SMS Pharmaceutica ls Limited ("the Company" ), for the quarter and nine month period ended 31" December 2019 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Compa ny's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) " Interirn Pinancial Reporting" prescribed under section 133 of the Cornpanies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles genera lly accepted in India. Our responsibility is to express a conclusion on the Staternents based on our review.

We conducted our review of the Staternent in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Fi nancia l information perforrned by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard req uires that we plan and perform the review to obtain rnoderate assurance as to whether the Statements is free of material misstatement. A review of the interim financia l information consists of making inquires primarily of cornpanies personnel responsible for financial and accounting mattes, and applying ana lytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified uls 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant rnatters tl,at rnight be identified in an audit. Accordingly we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accornpanying statement, prepared in accordance with the recognition and rneasurernent principles laid down in the aforesaid Indian Accou nting standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with releva nt rules issued there under and other accounting principles generally accepted in India, has not disclosed tl,e information required to be disclosed in terrns of the Listing Regulations, including the manner in which it is to be disclosedl or that it contains any material misstatement.

Place: Hyderabad Date: 12-02-2020

Partner

U Dr. M. No. 227679 . tv ', 2..()22-1-.6 j-CJ AAAAA L )1 g

Flat # C2, Millenium House, # 8-2-601/B, Road No. 10, Near Zaheer Nagar Cross Road , Banjara Hills, Hyderabad - 500 034 . • : 040-233867Q3 / 23386784 C8J : suryanarayanasuresh@gmail.com

Limited Review Report

To the Board of Directors SMS Pharmaceuticals Limited

• 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of SMS Pharmaceuticals Limited (" the Parent") and share of the net profit after tax and total comprehensive income of its associates for the quarter ended 31,1 December, 2019 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBl (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
• 1. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Inlerim Financial infimllation performed by tlie Independent Auditor of tlie Entih), issued by Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

• 1. The Statement includes the result of the following Associates:
  • a. VKT Pharma Private Limited

Flat # C2, Millenium House, # 8-2-601/B, Road No. 10, Near Zaheer Nagar Cross Road, Banjara Hills, Hyderabad - 500 034. ~ : 040-233867B3/ 23386784 [8J : suryanarayanasuresh@gmail.com

• 1. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the considera lion of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be clisclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or tha t it contains any material misstatement.
• 1. We did not review the interim financial statements of associate included in the consolidated unaudited financial results, whose interim financial statements reflects the Group's share of net profit after tax of Rs. 11.70 lakhs and total comprehensive income of Rs. 28.39 lakhs for the quarter ended 31st December, 2019 as considered in the consolida ted unaudited financial results, in respect of associa te, whose interim financial statements have not been reviewed by us. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of the associate is based solely on the reports of the other auditors an d the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

Place: Hyderabad Da te: 12-02-2020

For Suryanarayana & Suresh., Chartered Accountants Reg. NO.006631S ~ Nagendra Rao

V Partner M. No. 227679

UD.l-f0: 2-022.-::f-61'1 AAAAA rYl f 59G"